One-year outcomes of treat-and-extend regimen with intravitreal aflibercept 8 mg for treatment-naïve neovascular age-related macular degeneration - PubMed
an hour ago
- #aflibercept
- #macular degeneration
- #ophthalmology
- One-year outcomes of treat-and-extend (TAE) regimen with intravitreal aflibercept 8 mg for treatment-naïve neovascular age-related macular degeneration (nAMD) were evaluated.
- 72.3% of eyes completed treatment, showing significant improvements in best-corrected visual acuity (BCVA), and reductions in foveal thickness (FT) and central choroidal thickness (CCT).
- Average total injections over 1 year were 6.5 ± 0.7, with a final intended injection interval of 13.4 ± 3.3 weeks.
- 10.8% of eyes discontinued treatment due to non-infectious intraocular inflammation (IOI) with retinal vasculitis during the loading phase.
- 8.4% were switched to brolucizumab due to persistent exudation on 8-week aflibercept intervals, and 8.4% dropped out.
- The regimen is effective but requires careful monitoring for IOI and may be insufficient for some exudative changes.